BRCA1 and serous adenocarcinoma: Using maintenance therapy with a PARP inhibitor provide more favorable progression-free survival among women with high-grade serous carcinoma (HGSC) and a BRCA1/2 mutation and homologous-recombination deficiency (HRD).